Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.71 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071184 | 0.84 | DPP4 (0.98) | DPP4DPP8DPP7DPP9 | |
| Hydrochloric Acid SCHEMBL6915483 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL12767550 | 0.82 | DPP4 (0.78) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL13593625 | 0.80 | DPP4 (0.84) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8362759 | 0.79 | DPP4 (0.66) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL1509247 | 0.79 | DPP4 (0.71) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL7061963 | 0.79 | DPP4 (0.71) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL2667453 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL15024075 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL12767535 | 0.77 | DPP4 (0.68) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20110190308-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | MERCK & CO., INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190308-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 4/4885DPP7 3/4885 |
| US-20200206221-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-20080125403-A1 | Method of Treating Men with Metabolic and Anthropometric Disorders | CYP17A1, SHBG, CYP21A2 | DPP4 158/4885DPP8 378/4885DPP7 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.